Member Info for amones

Hutchmed has expressed its intentions of “associating” with other major pharma. AZ is keen to widen its investment in China. Further approvals from the NDA should make HCM a much more valuable and attractive asset.

Looking at the significant volumes traded (with sp climbing at the same time) during last week and today, it won’t be wrong to assume that it could be shorts getting covered by the institution/s. Its good news at this time, because these financial institutions have better source of knowledge and research. Fingers crossed for some good news in the coming days. No recommendation intended.

Massive volume at HKSE 31.5 millions so far.

Thanks pencil for that information. So, it is not an exclusive problem of HCM?

Why there have been so many ‘buys’ today, if we can believe the data on this page as correct. Who are these buyers?

Sad state of affairs. Not even a single word from the board of directors.

This morning’s trading has number of buys going through. Appears investors are making use of the lowest sp in the last 10 years. Company’s website has number of news and presentations. Out of that lengthy list, market is waiting for some material news to come out in support of the sp. I am eagerly waiting for Surufatinib bridging studies in Europe and USA. Hope those are in progress. In China, company had to prematurely close the studies because of reaching expected clinical outcome well in advance. Come on directors, keep the market informed.

0013.HK finding resistance around HK$13. Decent volume of trade at HKSE (?mostly buys) today. Either shorts being closed or accumulation at favourable price.

Thanks pencil for this information. However, I doubt if anyone would be able to reply, unless, it is in their job description. Have you ever received a reply from the company for your query?

Wondering about the reasons for all the major holders continue to maintain their positions. What prospects are they looking for after this disappointing show. Unfortunately, we don’t get to hear from them. Any opinions?

Its a Shame. I was going through the news and presentations on Hutcmed website. There is information about dozens of phase 2, 3 clinical studies, many jointly conducted along with well known names and few international bridging studies available on the site. Are all those drug invented are of absolute zero value? Are the markets not able to appreciate the revenues generated from sales within mainland China?
If the board wants to keep this company alive, directors should buy in the open market as they used to do 8 years ago. It is the least they should be doing right now.

Thanks pencil for explaining issues around auditing, SEC and also for posting the link to check major shareholders. I checked the link yesterday and it came up with share holding information with yesterday’s date. Noticed previous CEO, Mr Hogg holding more than 11 millions and many other individuals and funds holding quite a lot. Hopefully better prospects are ahead.

(I had read about Chinese belief about 13 being a lucky number and that was the reason for the company seeking 0013 as its stock code. Let’s hope Chinese belief comes true!)

“Auspicious” number stock, 0013 has reached (un)lucky share price of 13 HK$. It was traded at 70 HK$ when listed at HKSE! Perhaps, time to repeat Davey’s question, why not a ‘buy out’? Are the assets so worthless?

Thanks to pencil and Davey .
Pencil, are you able briefly explain how HCM would be affected by the information in your last two posts. (Sorry for being naïve and ignorant (;-)

Could someone please share a link to the information of latest numbers of shares held by the directors and other major shareholders? Are the ‘cornerstone’ investors (who invested few hundreds of millions and bought at prices of $25 per ADR) still holding?

Lack of adequate PR coverage is certainly a factor. All those directors are neither saying anything to prevent further falls in the sp nor buying loads of shares in the open market. Are they not concerned while the sp is dwindling down to the lowest in the last decade?

As stated by the company, they must be searching for a suitable partner for launching their products at a global level. Let’s hope it’s going to be a major player in the field.
The malaise mentioned by Davey, started worsening with the departure of Mr Hogg. PR was extremely good and effective while he was in charge. That could be one of the reasons for the excellent (and indeed a true) market valuation. Is it not tough for the chief scientific officer to manage the CEO duties and also to lead a big team of research scientists? To gain back decent market valuation, company (with clinically proven and marketed therapeutic agents and many more in the pipeline), needs a dedicated CEO and a robust PR workforce. Someone with experience and links in the field will be an excellent choice. Of course, merger with a major group would do a great deal of benefit in all respects. Hopefully, major shareholders and board of directors are able to give it a thought.

Any relevance to Hutchmed, Pencil?

So, it’s not just Hutchmed that has been affected. Today’s utterly poor market valuation status (in spite of great pipeline) should make it compelling to the company to go for an arrangement with a global partner as soon as possible. Why is the PR so quiet?

What is happening??